Immunome, Inc. (NASDAQ:IMNM) Receives Average Rating of “Buy” from Brokerages

Shares of Immunome, Inc. (NASDAQ:IMNM) have earned an average rating of “Buy” from the seven brokerages that are covering the company, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $25.14.

A number of research analysts have weighed in on IMNM shares. Stephens reaffirmed an “overweight” rating and set a $30.00 price target on shares of Immunome in a research report on Thursday, March 20th. Guggenheim decreased their price target on shares of Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, March 20th. Lake Street Capital started coverage on Immunome in a research note on Wednesday, April 2nd. They set a “buy” rating and a $23.00 price objective on the stock. Wedbush reiterated an “outperform” rating and set a $33.00 target price on shares of Immunome in a report on Thursday, March 20th. Finally, Lifesci Capital started coverage on Immunome in a report on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price target for the company.

Insider Buying and Selling at Immunome

In related news, CTO Philip Tsai bought 12,300 shares of the firm’s stock in a transaction that occurred on Monday, March 24th. The stock was purchased at an average price of $8.42 per share, for a total transaction of $103,566.00. Following the transaction, the chief technology officer now directly owns 33,300 shares of the company’s stock, valued at approximately $280,386. This represents a 58.57 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Clay B. Siegall purchased 137,100 shares of Immunome stock in a transaction dated Wednesday, March 26th. The stock was bought at an average cost of $7.29 per share, with a total value of $999,459.00. Following the completion of the purchase, the chief executive officer now owns 806,736 shares in the company, valued at approximately $5,881,105.44. This trade represents a 20.47 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 306,400 shares of company stock worth $2,322,995 over the last ninety days. Company insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Immunome

Several hedge funds have recently modified their holdings of the company. GAMMA Investing LLC boosted its stake in Immunome by 2,822.9% during the first quarter. GAMMA Investing LLC now owns 6,138 shares of the company’s stock valued at $410,000 after buying an additional 5,928 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in Immunome in the 4th quarter valued at about $70,000. KLP Kapitalforvaltning AS bought a new position in shares of Immunome during the 4th quarter valued at about $75,000. AlphaQuest LLC grew its stake in shares of Immunome by 786,700.0% in the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock worth $84,000 after purchasing an additional 7,867 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Immunome by 482.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock worth $91,000 after purchasing an additional 7,129 shares in the last quarter. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Immunome Stock Performance

Shares of IMNM stock opened at $6.21 on Friday. The firm has a market capitalization of $539.97 million, a price-to-earnings ratio of -0.77 and a beta of 2.05. Immunome has a one year low of $5.15 and a one year high of $21.72. The company has a 50 day moving average price of $8.72 and a 200 day moving average price of $10.71.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). The firm had revenue of $2.74 million during the quarter, compared to analysts’ expectations of $3.07 million. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. As a group, equities analysts forecast that Immunome will post -2.21 EPS for the current fiscal year.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.